Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q4 FY25 results · Jan–Mar 2025
Wockhardt reported revenue from operations of ₹743.00 crore (up 6.1% from Q4 FY24) and net loss of ₹45.00 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 743.00 | 700.00 | +6.1% | 721.00 | +3.1% |
| Other income | 15.00 | 54.00 | −72.2% | 8.00 | +87.5% |
| Total income | 758.00 | 754.00 | +0.5% | 729.00 | +4.0% |
| Profit before tax | (22.00) | (180.00) | Loss narrowed | 21.00 | Turned loss |
| Net profit for the period | (45.00) | (177.00) | Loss narrowed | 20.00 | Turned loss |
| Attributable to shareholders of the company | (25.00) | (169.00) | Loss narrowed | 14.00 | Turned loss |
| EPS, basic (₹) | (1.57) | (11.64) | Loss narrowed | 0.91 | Turned loss |
| Net margin (%) | -6.1 | -25.3 | 2.8 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 355.00 | 355.00 | +0.0% | 325.00 | +9.2% |
| Other income | 14.00 | 24.00 | −41.7% | 6.00 | +133.3% |
| Total income | 369.00 | 379.00 | −2.6% | 331.00 | +11.5% |
| Profit before tax | 40.00 | (126.00) | Turned profit | (22.00) | Turned profit |
| Net profit for the period | 40.00 | (126.00) | Turned profit | (22.00) | Turned profit |
| EPS, basic (₹) | 2.47 | (8.71) | Turned profit | (1.40) | Turned profit |
| Net margin (%) | 11.3 | -35.5 | -6.8 |
Consolidated
- Filed with BSE
- 29 May 2025, 17:54 IST
- Board meeting
- 29 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 May 2025, 17:54 IST
- Board meeting
- 29 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE